To assess the prevalence and potential risk factors of latent tuberculosis infection (LTBI) in Chinese patients with inflammatory bowel disease (IBD) and to evaluate the role of chest computed tomography (CT) in the screening of LTBI.
INTRODUCTION
The incidence and prevalence of inflammatory bowel disease (IBD) are increasing with time around the world and several countries in East Asia have experienced a more than double increase of the disease over the past decade.
1,2 Therefore, IBD is associated with a substantial healthcare burden that affects patients, healthcare systems and society in general. The increasing use of immunomodulators and anti-tumor necrosis factor (TNF) agents has revolutionized the treatment of IBD, but the potential risks of opportunistic infections pose new challenge for clinicians. 3 Screening for hepatitis B and latent tuberculosis infection (LTBI) should be considered before starting immunomodulator therapy or biologics, according to the European Crohn's and Colitis Organisation (ECCO) guideline. 4 On the other hand, one-third of the world population is estimated to be infected with Mycobacterium tuberculosis (M. tuberculosis). 5 Annual rates of infection vary from 4.2% in South Africa and 1.7% in Vietnam to 0.03% in the USA. 5 China has the second highest tuberculosis (TB) burden worldwide with a 0.9-1.1 million incidence of active TB, accounting for 12% of global cases in 2010. 6 IBD patients in China not only face the risks of opportunistic infections associated with biological agents, but also need to undergo the differential diagnosis from intestinal TB. Thus, there is much work to do to identify LTBI.
LTBI is defined as a state of persistent immune response to stimulation by M. tuberculosis antigens without clinical evidence of active TB. 7 Currently, there is no gold standard for the diagnosis of LTBI. It is usually diagnosed by the tuberculin skin test (TST) or interferon-γ release assay (IGRA) according to the response to in vivo or in vitro stimulation by M. tuberculosis antigens. The TST has poor specificity in populations vaccinated with Bacillus CalmetteGuérin (BCG) and has poor sensitivity in immunocompromised patients. IGRA may be associated with less false-positive results than the TST. However, recent studies involving serially tested healthcare workers in the USA have shown that false conversions and reversions are more common with IGRA than with TST. 8 Furthermore, some patients developed active TB despite negative TST and IGRA results. 9 The question is whether any other screening strategies can improve LTBI detection. The objectives of this study were: (i) to assess the prevalence of LTBI in China; (ii) to investigate the risk factors associated with LTBI; (iii) to calculate the rates of reversion and conversion in serial testing data; and (iv) to evaluate the value of chest computed tomography (CT) in the screening for LTBI.
PATIENTS AND METHODS

Patients and data collection
This was a retrospective, observational study. All IBD patients who had received T-SPOT.TB test from December 2011 to January 2016 were included. IBD was diagnosed according to the ECCO consensus.
Patients with active TB (either pulmonary or extrapulmonary) at baseline were excluded. Detailed information was obtained from each patient, including their characteristics and other clinical information such as the Montreal classification of IBD, their personal history of TB, surgical history, immunosuppressive therapy and relevant laboratory results.
This study was approved by the Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiao Tong University (Shanghai, China).
Definitions
LTBI was defined as the presence of at least one positive result of T-SPOT.TB test or chest CT screening. T-SPOT.TB conversion was defined as the change from negativity to positivity, and reversion was the change from positivity to negativity, as proposed in the guidelines. 8 Immunosuppressive therapy was defined as 20 mg/day of prednisone or equivalent for 2 weeks or longer within the last 3 months, any dose of azathioprine, methotrexate, thalidomide or cyclosporine within the last 3 months and biologic agents within the last 12 weeks before T-SPOT.TB test.
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LTBI screening tests
T-SPOT.TB
The enzyme-linked immune spot release assay was performed using the commercially available T-SPOT.TB kit (Oxford Immunotec, Oxford, UK) in accordance with the manufacturer's instructions. In brief, peripheral blood mononuclear cells (PBMCs) were isolated from 5 mL heparinized peripheral blood. Freshly isolated PBMCs were re-suspended in cell culture medium and incubated with specific TB antigens (the 6 kDa early secretory antigenic target [ESAT-6], the 10 kDa culture filtrate antigen and phytohemagglutinin) and negative (nil) control in wells pre-coated with antibody to interferon (IFN)-γ for 16-20 h at 37 C in a humidified 5% carbon dioxide incubator. The wells were washed and alkaline phosphatase-labeled mouse anti-human IFN-γ antibody (Oxford Immunotec) was added to each well. The plates were then incubated at 2-8 C for 1 h. Substrate solution was added to each well after the plates were washed and incubated at room temperature for 7 min. A digital microscope was used to measure the number of spots in each well. Results were interpreted by subtracting the spot count in the nil control from the spot count in panels A and B. A DJ Song et al.
Journal of Digestive Diseases 2017; 18; 23-30 result was considered positive when the test wells contained at least six spots more than the nil control if the nil well had less than 5 spots, or at least twice the nil control if the nil well had ≥6 spots.
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Chest CT
The chest CT image was interpreted by an experienced radiologist. CT findings indicative of LTBI included apical or basal pleural thickening, fibrotic scarring, apical densities, calcified nodules or mediastinal or hilar lymphadenopathy.
Statistical analysis
Statistical analyses were performed using SPSS 19.0 (IBM, Armonk, NY, USA). Categorical variables were expressed as numbers and percentages and analyzed by tge χ 2 test and R × C contingency tables. Continuous variables were summarized in the form of mean AE standard deviation (SD). If a variable appeared to be associated with positive T-SPOT.TB results in the univariate analysis (P < 0.10), it was further evaluated in the multivariate analysis to identify the risk factors. P < 0.05 was considered statistically significant.
RESULTS
Patients' characteristics
A total of 534 IBD patients were included between December 2011 and January 2016, including 300 with Crohn's disease (CD), 187 with ulcerative colitis (UC) and 47 with IBD type unclassified (IBDU). The patients' characteristics are summarized in Table 1 . The participants had a mean age of 39.6 years, and were predominantly males (63.3%). The disease phenotype (behavior and location) was evaluated according to the Montreal Classification scheme. The proportions of CD patients with inflammatory (B1), stricturing (B2), penetrating (B3), B2 together with B3, and perianal disease were 20.3% (n = 61), 27.0% (n = 81), 6.0% (n = 18), 7.3% (n = 22) and 39.4% (n = 118), respectively. While the proportions of CD patients with L1 (terminal ileum), L2 (colon), L3 (ileocolon) and L4 (upper gastrointestinal tract) were 41.7% (n = 125), 7.7% (n = 23), 46.3% (n = 139) and 4.3% (n = 13), respectively. For UC patients, colonoscopy result was unavailable in one patient. Thus, the proportions of those with E1 (ulcerative proctitis), E2 (left-sided UC) and E3 (extensive UC) were 11.3% (n = 21), 37.1% (n = 69) and 51.6% (n = 96), respectively. At the time of LTBI screening, 18.0% (n = 96) of patients were under immunosuppressive therapy, among whom 2.4% (n = 13) were treated with two or more immunosuppressive agents, mostly thiopurines and steroids.
Prevalence of LTBI based on T-SPOT.TB
T-SPOT.TB result was found to be positive in 42 UC, 39 CD and 15 IBDU cases. The overall prevalence rate of LTBI based on T-SPOT.TB was 18% ( Table 2 ). The prevalence rate of LTBI was significantly higher in the UC group than in the CD group (22.5% vs 13.0%, P = 0.006). Among IBD patients, T-SPOT.TB was found to be positive in 19.1% (61/320) of treatment-naive patients and 16.4% (35/214) of patients who were not (P = 0.425). Furthermore, the positive rate of T-SPOT.TB was not affected by immunosuppressive therapy (12.5% for patients with immunosuppressive therapy vs 19.2% for those without, P = 0.123).
Multivariate analysis of factors associated with T-SPOT.TB results
Logistic regression analysis was performed to identify factors that were associated with positive T-SPOT.TB results. Age, duration of IBD, history of TB and oral immunosuppressants were significantly associated with T-SPOT.TB positivity in the univariate analysis (Table 3) . However, all the abovementioned factors except the duration of IBD remained significant in Of the 534 patients, 123 were serially screened with T-SPOT.TB assay. The initial positivity of T-SPOT.TB was 28.5% (35/123). Of the 123 participants, 78 were consistently negative, 20 were consistently positive and the conversion and reversion rate of T-SPOT.TB was 10.2% (9/88) and 42.9% (15/35), respectively. Interestingly, a patient with CD showed conversion followed by reversion without chemoprophylaxis (Table 4) . Among the nine conversion patients, one received INH therapy owing to patchy nodular of the upper lobe on the chest CT at baseline even though the T-SPOT.TB result was negative. Of the 15 patients with reversion, three reverted to negativity without prophylaxis, two were prescribed INH treatment, one was prescribed double anti-TB drugs, five were prescribed triple anti-TB drugs and four received quadruple therapy. Twelve of 20 patients who were consistently positive were given prophylaxis with a follow-up interval from 3 to 48 months.
The efficacy of chest CT in the screening for LTBI
Among the 534 participants who had available T-SPOT.TB results, 447 (83.7%) also underwent chest CT. Altogether 102 of 447 (22.8%) patients were found with abnormalities suggestive of LTBI on chest imaging. Among these patients, 43 showed fibrotic scarring, 55 showed pleural thickening, 32 showed calcified nodules, 15 apical densities, and nine mediastinal or hilar lymphadenopathy (Table 2) . Overall, 38 participants were positive for both the T-SPOT.TB test and chest CT, 297 were negative for both. The other 112 had discordant results, including 64 with abnormalities on chest CT but negative T-SPOT.TB, and 48 with normal chest CT results but positive T-SPOT.TB. Kappa coefficients for evaluating the concordance between T-SPOT.TB results and chest CT findings showed that the concordance rate was 75%, with a kappa value of 0.25 (95% CI 0.15-0.35).
Furthermore, among typical CT findings of LTBI, the concordance rate between calcified nodules and T-SPOT.TB test was 62.7% with a kappa value of 0.18. Of the nine patients who had T-SPOT.TB conversions on serial testing, 6 (66.7%) showed abnormal chest CT findings suggestive of LTBI at baseline (Table 5) .
DISCUSSION
Despite a sustained fall in TB incidence during the last decade, there were 8.8 million instances of TB worldwide in 2010, representing 178 cases per 100 000 population. 12 A population-based study showed an overall TB infection rate of 18.8% measured by QuantiFERON-TB gold (QFT-G) in China, which has been estimated to have one million new cases of TB every year, more than any country except India. 13 Screening for latent TB, mainly by TST or IGRA, prior to anti-TNF therapy has been proven to be effective in reducing the number of active TB infection. To our knowledge, this is the first study to systematically explore the role of a screening strategy for LTBI by T-SPOT.TB, not only for prevalence and related risk factors, but also for T-SPOT.TB conversion/reversion.
In the present study, the overall positive rate of T-SPOT.TB in IBD patients was 18.0%. Wong et al.'s study 14 which was conducted on IBD cases from Hong Kong SAR, China reported a similar result (21.9%). These two regions may also have a similar prevalence of TB. Studies conducted in the USA and Europe reported lower rates ranging from 1.5% to 14.1%. 15, 16 What is worth mentioning was that there was a higher IGRA-positive rate in UC patients than in CD patients (22.5% vs 13.0%). However, Pagliaro et al. 17 reported an opposite result. We supposed that UC patients in our region might receive less immunosuppressive therapy and the number of included patients was small.
Many risk factors have been demonstrated to influence the results of IGRA in routine screening for LTBI in IBD patients, such as older age, body mass index (BMI), BCG vaccination, signs indicative of LTBI on chest X-ray, immunosuppressive therapy and appendectomy. 10, 18 In our cohort, patients treated with immunosuppressive therapy had a lower positive rate than those who did not, but the difference did not reach statistical significance (12.5% vs 19.2%, P = 0.123). This was in consistent with the findings of some studies, [19] [20] [21] but not with others. 10, 14 Recently, a meta-analysis also concluded that QFT-G was negatively influenced by immunosuppressive therapy in autoimmune diseases and a similar trend was observed for T-SPOT.TB, but it did not reach statistical significance. 22 However, the high heterogeneity of the included studies with regard to the definition of immunosuppressive therapy restricted the interpretation of these results. Furthermore, we performed a subgroup analysis of different medications. We found that immunosuppressants had a negative influence on T-SPOT.TB assay, but no similar results were observed for steroids and infliximab. Unfortunately, the number of IBD patients treated with infliximab was too small for further analysis.
Current guidelines did not provide a clear and consistent recommendation for serial testing. A systematic review showed that irrespective of TB incidence rates in the study's country of origin, reversion rates were consistently higher than conversion rates (22-71% vs 1-14%) in healthcare workers. 23 Our study demonstrated that IGRA conversions occurred in 7.3% (9/123), whereas IGRA reversions were seen in 12.2% (15/123) of IBD patients. Previous clinical trials demonstrated that INH monotherapy for LTBI substantially reduced the probability of developing active TB. 24 However, treatment of LTBI with INH monotherapy is also known to promote the development of INH-resistant TB. Nevertheless, it is not known how to avoid overexposure to chemoprophylaxis. Some studies have demonstrated that participants with baseline results around the diagnostic threshold (between four and eight spotforming cells) were more likely to show inconsistent results on retesting. 23 Our study showed that the conversion rates were reduced from 10.2% to 6.8% and the reversion rates from 42.9% to 40% using a similar borderline zone (8-10 spot-forming cells). This observation is in accordance with the findings of one current study of German healthcare workers. 25 The problem is whether the risk of LTBI reactivation will increase. Schablon et al. 25 showed that none of the 287 participants in their study developed active TB during a follow-up period of more than 2 years. However, we need to further investigate the role of an uncertainty zone around the cut-off point in IBD patients with biological therapy.
On the other hand, although it is not the gold standard for the diagnosis of LTBI, IGRA is thought to be more accurate and cost-effective compared with the traditional TST. 26 Low sensitivity and poor reproducibility are challenges that physicians confront using the test. 27 More effective screening strategies are urgently needed. The combination of the QFT-G test and chest CT is widely used in clinical practice in TB diagnosis. 28 However, LTBI screening procedures integrating both the T-SPOT.TB and chest CT are rarely reported. Typical CT findings of active post-primary pulmonary TB include centrilobular nodules and branching linear structures (treein-bud appearance), lobular consolidation, cavitation and bronchial wall thickening. 29 Evidence of prior TB infection included apical or basal pleural thickening, fibrous scarring, calcified nodules, calcified lymph nodes, or both, and noncalcified nodules. 30 In this study we also evaluated the potential prevalence of LTBI using chest CT as well as the IGRA test. The concordance rate was 75% between the chest CT and T-SPOT.TB. Among the five typical CT findings of LTBI, calcified nodules are more effective for LTBI screening (the concordance rate is 62.7%; kappa value 0.18).
This study had several limitations. First, there are no healthy controls in our study. We reported the prevalence of LTBI in Chinese patients with IBD, but we cannot provide data for its prevalence in the background population. A study from a same region reported that the overall TB infection rate among patients with rheumatic diseases was 9.0% (28/311). 11 Another study from Hong Kong showed that IGRA was positive in 45 of 234 healthy controls.
14 Second, this is a retrospective study, some data such as the BCG vaccination were not available.
Third, we recommended that chest CT might be used to screen the LTBI of IBD patients besides IGRA. However, chest CT is not widely accepted by the patients suspected of having LTBI owing to ionizing radiation. Thus, we suggested that chest CT should be performed in high-prevalence regions.
In conclusion, the prevalence of LTBI in IBD patients is high in China. Chest CT is recommended as an alternative to IGRA for screening LTBI in IBD patients. before commencing immunosuppressive therapy in high-prevalence regions.
